GRI Bio, Inc. GRI

GRI Company Overview

GRI Bio, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing immunology-based therapies for inflammatory, fibrotic, and autoimmune diseases. The company’s research centers on targeting invariant natural killer T (iNKT) cells, a subset of immune cells believed to play a role in regulating inflammatory and fibrotic responses. GRI Bio operates within the biotechnology and biopharmaceutical industries, with an emphasis on developing small-molecule therapies and immune-modulating drug candidates for diseases with limited treatment options.

The company’s primary value drivers are its proprietary iNKT agonist and antagonist development programs, including pipeline candidates designed for conditions such as idiopathic pulmonary fibrosis and other chronic inflammatory disorders. GRI Bio evolved through a series of biotechnology-focused corporate developments and public market transactions that positioned the company as a Nasdaq-listed clinical-stage therapeutics developer. Public disclosures and regulatory filings indicate that its strategy is centered on advancing preclinical and clinical assets rather than generating commercial product revenue at this stage.